Possibilities of Some Probiotic Strains in the Eradication of  Helicobacter Pylori in Vitro and in Vivo

Suvorov, Alexander; Барышникова, Н. В.; ), ); Сварваль, А В; Nijazov, R.M. Nijazov

doi:10.18565/pharmateca.2018.2.74-78

Cited by 3 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Применение пробиотического штамма Enterococcus faecium L3 приводило к увеличению доли успешной эрадикации на 15% [71]. Комплексы пробиотических штаммов оказывали положительное влияние на исход терапии [52,[72][73][74]. При использовании штамма Lactobacillus rhamnosus GG значимого усиления эрадикационного эффекта выявлено не было [69,75,76].…”

Section: пробиотики в качестве дополнительной терапииunclassified

Eradication therapy of helicobacteriosis with probiotics, problems, and prospects

Ermolenko

Молостова

Gladyshev

2021

jour

View full text Add to dashboard Cite

Currently, there is an urgent question of optimizing the treatment of stomach diseases associated with Helicobacter pylori, due to the increasing resistance of the pathogen to antibiotics and the presence of side effects of standard therapy. To optimize it, it is proposed to use probiotics as an additional or monotherapy. The review presents the results of studies of anti-helicobacter activity by in vitro and in vivo systems, as well as an assessment of the clinical effectiveness of various probiotic strains of microorganisms in eradication therapy. Several mechanisms of action of probiotics in the treatment of HP-related diseases are discussed. The problems and prospects of using personalized therapy of helicobacteriosis with probiotics and autoprobiotics, based on strains obtained from the gastrointestinal tract, are indicated.

show abstract

Section: пробиотики в качестве дополнительной терапииunclassified

Eradication therapy of helicobacteriosis with probiotics, problems, and prospects

Ermolenko

Молостова

Gladyshev

2021

jour

View full text Add to dashboard Cite

show abstract

The clinical effectiveness of probiotics and autoprobiotics in treatment of <i>Helicobacter pylori</i>-associated dyspepsia

Ermolenko

Молостова

Барышникова

et al. 2022

Russian Journal of Infection and Immunity

View full text Add to dashboard Cite

The aim of our study was to evaluate the clinical performance of a monotherapy by Enterococcus faecium-based probiotics and indigenous autoprobiotics against H. pylori associated dyspepsia. Materials and methods. There were examined 95 patients with dyspepsia. The entire patient cohort underwent clinical evaluation including filling out the questionnaire to assess dyspepsia symptoms before and after treatment, gastric endoscopy as well as gastric multi-focal biopsy (gastric body and gastric antrum) and verification of H. pylori infection with the three clinical laboratory methods (biochemical, bacteriological and molecular detection). An antagonistic in vitro activity of probiotics against H. pylori was detected by drop plate method for probiotic strains Enterococcus faecium SF68 and Bifidobacterium bifidum (Bifiform), Enterococcus faecium L3 (Laminolact), and autoprobiotic strains combined with indigenous Enterococcus faecium. To examine an antagonistic activity of probiotics and autoprobiotics in clinical trials, we used a starter culture based on the Enterococcus faecium L3 strain and an autoprobiotic based on indigenous Enterococcus faecium. The probiotic or autoprobiotic were administered orally to patients with gastritis twice a day at dose of 50 ml (8.0 lgCFU/ml) for 20 days. H. pylori eradication was assessed by stool antigen test 1.52 months after the end of treatment. Results. Initially the H. pylori infection was confirmed with 49.4% of patients. The sensitivity of H. pylori to the probiotics was detected in 81% of individuals for indigenous Enterococci (the autoprobiotic), 76% for Laminolact, and in 62% for Bifiform. 22 patients with previous history of allergic reactions to antibiotics used in routine H. pylori eradication regimens were divided in two cohorts. One cohort (10 patients) received the autoprobiotic only, another cohort (12 patients) received only probiotic. Monotherapy with autoprobiotic resulted in 100% H. pylori eradication, single-agent therapy with probiotic led to 60% eradication of H. pylori. Dyspepsia symptoms were completely resolved in both groups of patients. Conclusion. Our research demonstrated the sensitivity of examined H. pylori strains to be similar for traditional eradication treatment agents (antibiotics) and the proposed intervention agents (probiotics and autoprobiotics). An autoprobiotic monotherapy with indigenous enterococci led to higher levels of H. pylori eradication than with E. faecium L3-based probiotic agent. Our work demonstrated advantage for application of probiotics in patients with antibiotic allergies or other obstacles for the standard eradication therapy. Nonetheless, further investigation to better understand underlying mechanisms of action, as well as larger observational and randomized studies, are necessary to determine the scope of therapeutic application for probiotics and autoprobitics to eradicate H. pylori infection.

show abstract

“Old” and “new” probiotics in the treatment of gastroenterological diseases in children and adults: how to increase effectiveness?

Гончар

Alekhina

Suvorov

2021

jour

View full text Add to dashboard Cite

The purpose of the review is to analyze the real benefits of the use of traditional probiotics and to highlight the issues of the possibility of creating and using new generation probiotics in the treatment of gastroenterological pathology. Questions of effectiveness of therapy with traditional probiotics of functional and organic diseases of the gastrointestinal tract in children and adults from the points of view of evidence-based medicine are analyzed, insufficient number of studies in children and frequent absence of significant differences in the effect of probiotics compared to placebo are emphasized. New generation probiotic candidates are described, which could become potential sources of new drugs for various diseases, including gastroenterological pathology. The main problems in the way of creation and introduction of new probiotics are outlined. Data on an alternative approach of probiotic therapy based on use to restore microbiocenosis of own bacteria, which are grown as pure genetically characterized cultures and can be used as probiotic products, are presented.

show abstract

Possibilities of Some Probiotic Strains in the Eradication of Helicobacter Pylori in Vitro and in Vivo

Cited by 3 publications

References 0 publications

Eradication therapy of helicobacteriosis with probiotics, problems, and prospects

Eradication therapy of helicobacteriosis with probiotics, problems, and prospects

The clinical effectiveness of probiotics and autoprobiotics in treatment of <i>Helicobacter pylori</i>-associated dyspepsia

“Old” and “new” probiotics in the treatment of gastroenterological diseases in children and adults: how to increase effectiveness?

Contact Info

Product

Resources

About